The role of the immunosuppressant mycophenolate mofetil in pediatric renal transplant recipients;Der stellenwert des immunsuppressivums mycophenolatmofetil bei pädiatrischen nierentransplantatemprängern

Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft

Volumn 16, Issue 1, 2004, Pages 26-37

  Tönshoff, Burkhard ^a   Weber, L T ^a   Hocker B ^a   Kopf S ^a   Zimmerhackl, L B ^b   Armstrong, V W ^c   Oellerich, M ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Univ Klin Kinder Jugendheikunde   (Austria)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Immuno suppressive therapy; Mycophenolate mofetil; Pediatric renal transplantation; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

AREA UNDER THE CURVE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG TOLERABILITY; GRAFT REJECTION; GROWTH RETARDATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIPID METABOLISM; LIVER TOXICITY; MAINTENANCE THERAPY; METABOLIC DISORDER; MUTAGENICITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PEDIATRICS; POSTOPERATIVE CARE; REVIEW; SIDE EFFECT;

EID: 3543147108     PISSN: 09469648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Srinivas TR, Kaplan B, Meier-Kriesche HU (2003) Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 4: 2325-45
2. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-25
3. Sollinger HW (1995) US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225-32
4. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61: 1029-37
5. Bullingham RES, Nicholls A, Hale M (1996) Pharmacokinetics of mycophenolate mofetil (RS 61443): a short review. Transplant Proc 28: 925-29
6. Nowak I, Shaw LM (1995) Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41: 1011-17
7. Weber LT, Shipkova M, Lamersdorf T et al. (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 9: 1511-20
8. Bunchman T, Navarro M, Broyer M et al. (2001) The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 16: 978-84
9. Weber LT, Lamersdorf T, Shipkova M et al. (1999) Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit 21: 498-506
10. Shaw LM, Mick R, Nowack I, Korecka M, Brayman KL (1998) Pharmacokinetics of mycophenolic acid in renal transplant recipients with delayed graft function. J Clin Pharmacol 38: 268-75
11. Kaplan B, Meier-Kriesche HU, Friedman G et al. (1999) The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 39: 715-20
12. Zhu BT, Suchar LA, Huang MT, Conney AH (1996) Similarities and differences in the glucuronidation of estradiol and estrone by UDP-glucuronosyltransferase in liver microsomes from male and female rats. Biochem Pharmacol 51: 1195-02
13. McMillan JM, Shaddock JG, Casciano DA, Arlotto MP, Leakey JE (1991) Differential stability of drug-metabolizing enzyme activities in primary rat hepatocytes, cultured in the absence or presence of dexamethasone. Mutat Res 249: 81-92
14. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G (2002) Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62: 1060-67
15. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid Ther Drug Monit 23:119-28
16. Filler G, Zimmering M, Mai I (2000) Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 14: 100-4
17. Filler G, Lepage N, Delisle B, Mai I (2001) Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23: 514-9
18. Fruhwirth M, Fischer H, Simma B, Ellemunter H (2001) Elevated tacrolimus trough levels in association with mycophenolate mofetil-induced diarrhea: a case report. Pediatr Transplant 5: 132-4
19. Weber LT, Shipkova M, Armstrong VW et al. (2002) The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 13: 759-68
20. Shaw LM, Nicholls A, Hale M et al. (1998) Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 31: 317-22
21. Hale MD, Nicholls AJ, Bullingham RE et al. (1998) The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation, Clin Pharmacol Ther 64: 672-83
22. Cattaneo D, Gaspari F, Ferrari S et al (2001) Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15: 402-9
23. Weber LT, Shipkova M, Armstrong VW et al. (2002) Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 48: 517-25
24. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T (2001) Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23: 305-15
25. Shipkova M, Armstrong VW, Wieland E et al. (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126: 1075-82
26. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E (2000) Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 46: 365-72
27. Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M (1999) Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45: 419-22
28. Shipkova M, Wieland E, Schütz E et al. (2001) The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 33: 1080-81
29. Shipkova M, Armstrong VW, Weber L et al. (2002) Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 24: 390-9
30. Staskewitz A, Kirste G, Tönshoff B et al. (2001) Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. Transplantation 71: 638-44
31. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. (1999) A randomised double-blind, multicenter plasma concentration controlled study of the safety, and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68: 261-6
32. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM (1998) Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 65: 1127-9
33. Trompeter R, Filler G, Webb NJ et al. (2002) Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 17: 141-9
34. Jungraithmayr T, Staskewitz A, Kirste G et al. (2003) Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 75: 454-61
35. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-83
36. Powell KR (2000) Sepsis and shock. In: Nelson WE, Behrman RE, Kliegman RM, Jenson HB (Eds.) Nelson Textbook of Pediatrics (16th ed., pp. 747-51). Philadelphia, Pa: W.B. Saunders
37. Weber LT, Giurgea I, Bugert JJ, Mehls O, Tönshoff B (1999) Incidence of cytomegalovirus (CMV) infections in pediatric renal transplant recipients. Pediatr Nephrol 13: P252
38. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH (2002) Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 6: 396-9
39. Ducloux D, Motte G, Billerey C et al. (2002) Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int 15: 387-92
40. Abramowicz D, Manas D, Lao M et al. (2002) Cyclosporine withdrawal from a mycophenolate mofetil-containing inummosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 74: 1725-34
41. David-Neto E, Araujo LM, Lemos FC et al. (2001) Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 5: 302-9
42. Henne T, Latta K, Strehlau J, Pape L, Ehrich JH, Offner G (2003) Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 76: 1326-30
43. Höcker B, John U, Plank C et al. (2004) Successful withdrawal of steroids in pediatric renal transplant recipients under cyclosporin A and mycophenolate mofetil treatment: Results after four years. Transplantation (in press)
44. Broyer M, Guest G, Gagnadoux MF (1992) Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 120: 721-5
45. Jabs K, Sullivan EK, Avner ED, Harmon WE (1996) Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 61: 31-6
46. Ingulli E, Tejani AH (1994) Steroid withdrawal after renal transplantation. In: Tejani AH, Fine RN (Eds.) Pediatric renal transplantation (pp. 221-38). New York: Wiley Liss
47. Roberti I, Reisman L, Lieberman KV, Burrows L (1994) Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). Clin Transplant 8: 405-8
48. Grinyo JM, Gil-Vernet S, Serón D et al. (1997) Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 63: 1688-90
49. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G et al. (2002) Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 13: 1365-73
50. Budde K, Geissler S, Hallebach G, Waiser J, Fritsche L, Bohler T, Neumayer HH (2002) Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. Transplant Proc 34: 1703-5
51. Ojo AO, Meier-Kriesche HU, Hanson JA et al. (2000) Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405-9
52. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. (2003) Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 3: 68-73
53. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. (2003) Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75: 1341-6